Entero Therapeutics, Inc. (ENTO)
| Market Cap | 4.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.44M |
| Shares Out | 2.75M |
| EPS (ttm) | -31.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47,094 |
| Open | 1.730 |
| Previous Close | 1.770 |
| Day's Range | 1.730 - 1.910 |
| 52-Week Range | 1.700 - 33.800 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2024 |
About ENTO
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the deve... [Read more]
News
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
Late clinical-stage company to provide update on Phase 3 treatment for celiac disease Late clinical-stage company to provide update on Phase 3 treatment for celiac disease
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trials Presentations highlight new VCIEL scale to m...